Search Results - "Schwenke, C."

Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial by Zhou, Jin J, Schwenke, Dawn C, Bahn, Gideon, Reaven, Peter

“…There is uncertainty about the importance of glycemic variability in cardiovascular complications in patients with type 2 diabetes. Using the Veterans Affairs…”
Get full text

Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study by Saremi, Aramesh, Howell, Scott, Schwenke, Dawn C, Bahn, Gideon, Beisswenger, Paul J, Reaven, Peter D

“…To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with…”
Get full text

Diffusion-weighted imaging of focal renal lesions: a meta-analysis by Lassel, E. A., Rao, R., Schwenke, C., Schoenberg, S. O., Michaely, H. J.

“…Objectives Contrast-enhanced MRI can only distinguish to a limited extent between malignant and benign focal renal lesions. The aim of this meta-analysis is to…”
Get full text

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans by Koska, Juraj, Sands, Michelle, Burciu, Camelia, D'Souza, Karen M, Raravikar, Kalyani, Liu, James, Truran, Seth, Franco, Daniel A, Schwartz, Eric A, Schwenke, Dawn C, D'Alessio, David, Migrino, Raymond Q, Reaven, Peter D

“…GLP-1 receptor (GLP-1R) agonists may improve endothelial function (EF) via metabolic improvement and direct vascular action. The current study determined the…”
Get full text

Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis by REAVEN, Peter D, MORITZ, Thomas E, RAO, R. Harsha, SHAH, Jayendra H, GOLDMAN, Steven, REDA, Domenic J, MCCARREN, Madeline, ABRAIRA, Carlos, DUCKWORTH, William, SCHWENKE, Dawn C, ANDERSON, Robert J, CRIQUI, Michael, DETRANO, Robert, EMANUELE, Nicholas, KAYSHAP, Moti, MARKS, Jennifer, MUDALIAR, Sunder

“…Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary…”
Get full text

Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors by Saremi, Aramesh, Schwenke, Dawn C, Buchanan, Thomas A, Hodis, Howard N, Mack, Wendy J, Banerji, MaryAnn, Bray, George A, Clement, Stephen C, Henry, Robert R, Kitabchi, Abbas E, Mudaliar, Sunder, Ratner, Robert E, Stentz, Frankie B, Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A, Reaven, Peter D

“…OBJECTIVE—To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of…”
Get full text

p38α mitogen-activated kinase mediates cardiomyocyte apoptosis induced by palmitate by Oh, Charles C., Nguy, Michael Q., C. Schwenke, Dawn, Migrino, Raymond Q., Thornburg, Kent, Reaven, Peter

“…•Saturated fatty acids, including palmitate, are elevated in obesity and type 2 diabetes.•High palmitate level dose-dependently activates p38α MAPK in human…”
Get full text

Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk by DEFRONZO, Ralph A, TRIPATHY, Devjit, RATNER, Robert E, STENTZ, Frankie B, MUSI, Nicolas, REAVEN, Peter D, GASTALDELLI, Amalia, SCHWENKE, Dawn C, BANERJI, Maryann, BRAY, George A, BUCHANAN, Thomas A, CLEMENT, Stephen C, HENRY, Robert R, KITABCHI, Abbas E, MUDALIAR, Sunder

“…Individuals with impaired glucose tolerance (IGT) are at high risk for developing type 2 diabetes mellitus (T2DM). We examined which characteristics at…”
Get full text

Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data by Endrikat, J, Schwenke, C, Prince, M.R

“…Aim To assess the safety of gadobutrol administration in elderly patients (≥65 years) by comparing the incidence of adverse drug reactions (ADRs) following…”
Get full text

Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay by Oran, Paul E, Trenchevska, Olgica, Nedelkov, Dobrin, Borges, Chad R, Schaab, Matthew R, Rehder, Douglas S, Jarvis, Jason W, Sherma, Nisha D, Shen, Luhui, Krastins, Bryan, Schwenke, Dawn C, Reaven, Peter D, Nelson, Randall W

“…Insulin-like growth factor 1 (IGF1) is an important biomarker for the management of growth hormone disorders. Recently there has been rising interest in…”
Get full text

A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study by Tripathy, Devjit, Cobb, Jeff E, Gall, Walter, Adam, Klaus-Peter, George, Tabitha, Schwenke, Dawn C, Banerji, MaryAnn, Bray, George A, Buchanan, Thomas A, Clement, Stephen C, Henry, Robert R, Kitabchi, Abbas E, Mudaliar, Sunder, Ratner, Robert E, Stentz, Frankie B, Reaven, Peter D, Musi, Nicolas, Ferrannini, Ele, DeFronzo, Ralph A

“…Objective: The objective was to test the clinical utility of Quantose MQ to monitor changes in insulin sensitivity after pioglitazone therapy in prediabetic…”
Get full text

Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study by Belalcazar, L. Maria, Haffner, Steven M., Lang, Wei, Hoogeveen, Ron C., Rushing, Julia, Schwenke, Dawn C., Tracy, Russell P., Pi‐Sunyer, F. Xavier, Kriska, Andrea M., Ballantyne and the Look AHEAD (Action for Health in Diabetes) Research Group, Christie M.

“…Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive…”
Get full text

Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study by DeFronzo, R. A, Banerji, M. A, Bray, G. A, Buchanan, T. A, Clement, S, Henry, R. R, Kitabchi, A. E, Mudaliar, S, Musi, N, Ratner, R, Reaven, P, Schwenke, D. C, Stentz, F. D, Tripathy, D

“…Aims/hypothesis The aim of the study was to examine the determinants of oral glucose tolerance in 602 persons with impaired glucose tolerance (IGT) who…”
Get full text

Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study[S] by Belalcazar, L. Maria, Lang, Wei, Haffner, Steven M., Hoogeveen, Ron C., Pi-Sunyer, F. Xavier, Schwenke, Dawn C., Balasubramanyam, Ashok, Tracy, Russell P., Kriska, Andrea P., Ballantyne, Christie M.

“…Adipose tissue dysfunction plays a key role in the development of the metabolic abnormalities characteristic of type 2 diabetes (T2DM) and participates…”
Get full text

TREATMENT PATHWAYS OF DIFFUSE LARGE B‐CELL LYMPHOMA IN GERMAN CLAIMS DATA by Kurukulasuriya, N., Menzler, J., Schwenke, C., Neubauer, A.S., Boehnke, A.C.

Get full text

Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT) by Saremi, Aramesh, Anderson, Robert J, Luo, Ping, Moritz, Thomas E, Schwenke, Dawn C, Allison, Mathew, Reaven, Peter D

“…Abstract Aims The aim of the present study was to investigate the association of high-sensitivity C-reactive protein (CRP), interleukin-6 (IL-6) and…”
Get full text

Intra-individual randomised comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for preoperative breast MRI by Pediconi, F., Kubik-Huch, R., Chilla, B., Schwenke, C., Kinkel, K.

“…Objective To demonstrate non-inferiority of gadobutrol versus gadobenate dimeglumine by intra-individually comparing 0.1 mmol/kg body weight doses for…”
Get full text

Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed‐Methods Study by Dev, Sandesh, Hoffman, Trisha K., Kavalieratos, Dio, Heidenreich, Paul, Wu, Wen‐Chih, Schwenke, Dawn C., Tracy, Sarah J.

“…Background Mineralocorticoid receptor antagonists (MRAs) are the most underutilized pharmacotherapy for heart failure. Minimal data are available on the…”
Get full text

Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read by Koenig, M., Schulte-Altedorneburg, G., Piontek, M., Hentsch, A., Spangenberg, P., Schwenke, C., Harders, A., Heuser, L.

“…Objective To prove that 1.0 M gadobutrol provides superior contrast enhancement and MRI image characteristics of primary and secondary brain tumours compared…”
Get full text

Increasing fruits and vegetables to reduce mortality and promote independence by Schwenke, Dawn C.

Get full text